Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NGR-hTNF + cisplatin + pemetrexed
- Development stage
- Phase 2
- Lead developer
- AGC Biologics
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous
01
Overview
A combination therapy consisting of NGR-hTNF (tengonermin), cisplatin, and pemetrexed. NGR-hTNF is a vascular-targeting recombinant protein consisting of human Tumor Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide that selectively targets angiogenic tumor blood vessels through binding to CD13 isoform. It modifies the tumor microenvironment and increases intratumoral chemotherapy penetration and T-cell infiltration. Cisplatin and pemetrexed are chemotherapy drugs that destroy quickly dividing cells. This combination likely leverages NGR-hTNF's ability to improve tumor vasculature permeability to enhance the penetration and efficacy of cisplatin and pemetrexed.
- Brand names
- Tengonermin + cisplatin + pemetrexed
02
Targets
ANPEP (Aminopeptidase N)DNADHFR (Dihydrofolate reductase)TNFRSF1A (Tumor necrosis factor receptor superfamily member 1A)TNFR2 (Tumor necrosis factor receptor superfamily member 1B)TS (Thymidylate synthase)
Beyond the preview
Go deeper on NGR-hTNF + cisplatin + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NGR-hTNF + cisplatin + pemetrexed.